TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

From taking HRT to eating a healthy diet, Kate Muir shares some of the precautionary measures she's trying to avoid developing the same illness that took her mother Ella ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Erin Kelly, from Queensland, Australia, recently learned she had the disease after inheriting a rare genetic mutation called ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

The human and financial toll of Alzheimer's, Parkinson's, and other neurodegenerative diseases is growing by the day. Over 7 ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, ...